NASDAQ Healthcare Biotechnology TCRX

TScan Therapeutics, Inc.

$ 0.92 2.23 %

TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers. The company's pipeline features programs like TSC-100 and TSC-101, which are engineered to address blood cancers by clearing remnant leukemia cells and averting disease recurrence following hematopoietic stem cell transplantation. Additionally, TScan is advancing multiple candidates, including TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, targeting solid tumor indications. Beyond its oncology efforts, the company is also engaged in vaccine development for infectious agents, such as SARS-CoV-2. TScan has formed a strategic collaboration and licensing arrangement with Novartis Institutes for BioMedical Research, Inc., aimed at pinpointing novel cancer-specific antigens derived from the T cells of particular cancer patients. Founded in 2018, TScan Therapeutics, Inc. operates from its headquarters in Waltham, Massachusetts.

CEO: Gavin MacBeath - https://www.tscan.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$7.5 715.22 %

Recommandation

Buy

DCF

$ -4.12

Loading data...

TCRX vs S&P500

Loading data...

No data available.

Quick ratio

6.65

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-0.96

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.96

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-91.94 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-67.93 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

6.94

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.95

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.96

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
2 indicates worrying financial health
Altman score
-4.65 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
6.41 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.46 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.